| (1) |
Tunbridge WMG, Evered DC, Hall R, et al. The spectrum
of thyroid disease in a community: the Whickham survey. Clin Endocrinol
(Oxf) 1977; 7: 481-493. |
| (2) |
Wartofsky L, Glinoer D, Solomon B, et al. Differences
and similarities in the diagnosis and treatment of Graves' disease in Europe,
Japan and the United States. Thyroid 1991; 1: 129-135. |
| (3) |
Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon
DH. American Thyroid Association guidelines for use of laboratory tests
in thyroid disorders. JAMA 1990; 263: 1529-1532. |
| (4) |
Ruiz M, Rajatanavin R, Young RA, et al. Familial dysalbuminemic
hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis.
N Engl J Med 1982; 306: 635-639. |
| (5) |
Sakata S, Nakamura S, Miura K. Autoantibodies against
thyroid hormones or iodothyronine: implications in diagnosis, thyroid function,
treatment, and pathogenesis. Ann Intern Med 1985; 103: 579-589. |
| (6) |
Ross DS, Daniels GH, Gouveia D. The use and limitations
of a chemiluminescent thyrotropin assay as a single thyroid function test
in an out-patient endocrine clinic. J Clin Endocrinol Metab 1990; 71: 764-769. |
| (7) |
Nicoloff JT, Spencer CA. The use and misuse of the sensitive
thyrotropin assays. J Clin Endocrinol Metab 1990; 71: 553-558. |
| (8) |
Davies PH, Franklyn JA. The effects of drugs on tests
of thyroid function. Eur J Clin Pharmacol 1991; 40: 439-451. |
| (9) |
Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard
MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations
in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34: 77-83. |
| (10) |
Reinwein D, Benker G, Konig MP, Pinchera A, Schatz H,
Schleusener A. The different types of hyperthyroidism in Europe: results
of a prospective survey of 924 patients. J Endocrinol Invest 1988; 11: 193-200. |
| (11) |
Learoyd DL, Fung HYM, McGregor AM. Postpartum thyroid
dysfunction. Thyroid 1992; 2: 73-80. |
| (12) |
Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig
I. Induction of circulating activated suppressor-like T cells by methimazole
therapy for Graves' disease. N Engl J Med 1987; 316: 15-22. |
| (13) |
Kampmann JP, Hansen JM. Clinical pharmacokinetics of
antithyroid drugs. Clin Pharmacokinet 1981; 6: 401-428. |
| (14) |
Barnes HV, Bledsoe T. A simple test for selecting the
thioamide schedule in thyrotoxicosis. J Clin Endocrinol Metab 1972; 35:
250-255. |
| (15) |
Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari
Y, Fujishima M. Reevaluation of the effects of methylmercaptomidazole and
propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol
Metab 1987; 65: 719-723. |
| (16) |
Franklyn JA, Black EG, Wilson EM, Davis JRE, Sheppard
MC. Limitations of a sensitive assay for thyrotropin in managing patients
with thyroid disease. Clin Chem 1988; 34: 991-992. |
| (17) |
Dahlberg PA, Karlsson FA, Lindstrom B, Wide L. Studies
of thyroid hormone and methimazole levels in patients with Graves' disease
on a standardized anti-thyroid drug regimen. Clin Endocrinol (Oxf) 1981;
14: 555-562. |
| (18) |
Mashio Y, Beniko M, Ikota A, Mizumoto H, Kunita H. Treatment
of hyperthyroidism with a small single daily dose of methimazole. Acta Endocrinol
(Copenh) 1988; 119: 139-144. |
| (19) |
Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective
randomized trial of antithyroid drug dose in Graves' disease therapy. J
Clin Endocrinol Metab 1993; 76: 1516-1521. |
| (20) |
Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis
associated with antithyroid drugs: effects of patient age and drug dose.
Ann Intern Med 1983; 98: 26-29. |
| (21) |
Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced
agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol
(Oxf) 1989; 30: 525-530. |
| (22) |
Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid
drug-induced agranulocytosis: the usefulness of routine white blood cell
count monitoring. Arch Intern Med 1990; 150: 621-624. |
| (23) |
Liaw Y-F, Huang M-J, Fan K-D, Li K-L, Wu S-S, Chen T-J.
Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism:
a cohort study. Ann Intern Med 1993; 118: 424-428. |
| (24) |
Greer MA, Kammer H, Bouma DJ. Short-term antithyroid
drug therapy for the thyrotoxicosis of Graves's disease. N Engl J Med 1977;
297: 173-176. |
| (25) |
Sugrue D, McEvoy M, Feely J, Drury MI. Hyperthyroidism
in the land of Graves: results of treatment by surgery, radio-iodine and
carbimazole in 837 cases. Q J Med 1980; 49: 51-61. |
| (26) |
Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher
PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease:
long-term follow-up of 434 patients. Clin Endocrinol (Oxf) 1989; 31: 209-218. |
| (27) |
Teng CS, Yeung RTT. Changes in thyroid-stimulating antibody
activity in Graves' disease treated with antithyroid drugs and its relationship
to relapse: a prospective study. J Clin Endocrinol Metab 1980; 50: 144-147. |
| (28) |
Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid
drugs and Graves' disease: a prospective randomized evaluation of the efficacy
of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-679. |
| (29) |
Wilson R, McKillop JH, Henderson N, Pearson DW, Thomson
JA. The ability of the serum thyrotrophin receptor antibody (TRAb) index
and HLA status to predict long-term remission of thyrotoxicosis following
medical therapy for Graves' disease. Clin Endocrinol (Oxf) 1986; 25: 151-156. |
| (30) |
Weetman AP, Ratanachaiyavong S, Middleton GW, et al.
Prediction of outcome in Graves' disease after carbimazole treatment. Q
J Med 1986; 59: 409-419. |
| (31) |
Schleusener H, Schwander J, Fischer C, et al. Prospective
multicentre study on the prediction of relapse after antithyroid drug treatment
in patients with Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 689-701.
[Erratum, Acta Endocrinol (Copenh) 1989; 121: 304.] |
| (32) |
Young ET, Steel NR, Taylor JJ, et al. Prediction of
remission after antithyroid drug treatment in Graves' disease. Q J Med 1988;
66: 175-189. |
| (33) |
Tamai H, Nakagawa T, Fukino O, et al. Thionamide therapy in Graves' disease:
relation of relapse rate to duration of therapy. Ann Intern Med 1980; 92:
448-490. |
| (34) |
Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children
treated with long term medical therapy: twenty-five percent remission every
two years. J Clin Endocrinol Metab 1987; 64: 1241-1245. |
| (35) |
Wise PH, Marion M, Pain RW. Single dose, "block-replace" drug therapy
in hyperthyroidism. BMJ 1973; 4: 143-145. |
| (36) |
Hashizume K, Ichikawa K, Sakurai A, et al. Administration
of thyroxine in treated Graves' disease: effects on the level of antibodies
to thyroid-stimulating hormone receptors and on the risk of recurrence of
hyperthyroidism. N Engl J Med 1991; 324: 947-953. |
| (37) |
McDevitt DG, Nelson JK. Comparative trial of atenolol and propranolol
in hyperthyroidism. Br J Clin Pharmacol 1978; 6: 233-237. |
| (38) |
Murchison LE, How J, Bewsher PD. Comparison of propranolol
and metoprolol in the management of hyperthyroidism. Br J Clin Pharmacol
1979; 8: 581-587. |
| (39) |
Peden NR, Isles TE, Stevenson IH, Crooks J. Nadolol in thyrotoxicosis.
Br J Clin Pharmacol 1982; 13: 835-840. |
| (40) |
Philippou G, Koutras DA, Piperingos G, Souvatzoglou
A, Moulopoulos SD. The effect of iodide on serum thyroid hormone levels
in normal persons, in hyperthyroid patients, and in hypothyroid patients
on thyroxine replacement. Clin Endocrinol (Oxf) 1992; 36: 573-578. |
| (41) |
Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up
of treatment of thyrotoxicosis by three different methods. Clin Endocrinol
(Oxf) 1991; 34: 71-76. |
| (42) |
Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot
LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves'
disease. N Engl J Med 1984; 311: 426-432. |
| (43) |
Holm L-E, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism
long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982; 23:
103-107. |
| (44) |
Roudebush CP, Hoye KE, DeGroot LJ. Compensated low-dose
131I therapy of Graves' disease. Ann Intern Med 1977; 87: 441-443. |
| (45) |
Lowdell CP, Dobbs HJ, Spathis GS, McCready VR, Cosgrove DO, Harmer CL.
Low-dose 131I in treatment of Graves' disease. J R Soc Med 1985; 78: 197-202. |
| (46) |
Watson AB, Brownlie BEW, Frampton CM, Turner JG, Rogers
TGH. Outcome following standardized 185 MBq dose 131I therapy for Graves'
disease. Clin Endocrinol (Oxf) 1988; 28: 487-496. |
| (47) |
Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism
in Graves' disease. J Nucl Med 1991; 32: 411-416. |
| (48) |
Turner J, Sadler W, Brownlie B, Rogers T. Radioiodine
therapy for Graves' disease: multivariate analysis of pretreatment parameters
and early outcome. Eur J Nucl Med 1985; 11: 191-193. |
| (49) |
Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism:
long term follow up study. BMJ 1984; 289: 361-363. |
| (50) |
Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical
hyperthyroidism and reduced bone density as a possible result of prolonged
suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987;
82: 1167-1170. |
| (51) |
Franklyn JA, Sheppard MC. Thyroxine replacement treatment and osteoporosis.
BMJ 1990; 300: 693-694. |
| (52) |
Leese GP, Jung RT, Guthrie C, Waugh N, Browning MCK.
Morbidity in patients on L-thyroxine: a comparison of those with normal
TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992; 37: 500-503. |
| (53) |
Sawin CT, Geller A, Hershman JM, Castelli W, Bacharach P. The aging thyroid:
the use of thyroid hormone in older persons. JAMA 1989; 261: 2653-2655. |
| (54) |
Goolden AWG, Stewart JSW. Long-term results from graded
low-dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol
(Oxf) 1986; 24: 217-222. |
| (55) |
Hardisty CA, Jones SJ, Hedley AJ, Munro DS, Bewsher PD, Weir RD. Clinical
outcome and costs of care in radioiodine treatment of hyperthyroidism. J
R Coll Physicians Lond 1990; 24: 36-42. |
| (56) |
MacFarlane IA, Shalet SM, Beardwell CG, Khara JS. Transient
hypothyroidism after iodine-131 treatment for thyrotoxicosis. BMJ 1979;
2: 421-421. |
| (57) |
Hennemann G, Krenning EP, Sankaranarayanan K. Place of radioactive iodine
in treatment of thyrotoxicosis. Lancet 1986; 1: 1369-1372. |
| (58) |
Davies PH, Franklyn JA, Daykin J, Sheppard MC. The significance
of TSH values measured in a sensitive assay in the follow-up of hyperthyroid
patients treated with radioiodine. J Clin Endocrinol Metab 1992; 74: 1189-1194. |
| (59) |
Velkeniers B, Cytryn R, Vanhaelst L, Jonckheer MH. Treatment of hyperthyroidism
with radioiodine: adjunctive therapy with antithyroid drugs reconsidered.
Lancet 1988; 1: 1127-1129. |
| (60) |
Sridama V, DeGroot LJ. Treatment of Graves' disease
and the course of ophthalmopathy. Am J Med 1989; 87: 70-73. |
| (61) |
Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy
after treatment for Graves' hyperthyroidism. N Engl J Med 1992; 326: 1733-1738. |
| (62) |
Spencer RP, Chapman CN, Rao H. Thyroid carcinoma after
radioiodine therapy for hyperthyroidism: analysis based on age, latency,
and administered dose of I-131. Clin Nucl Med 1983; 8: 216-219. |
| (63) |
Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV.
Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism:
a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin
Endocrinol Metab 1974; 38: 976-998. |
| (64) |
Holm L-E, Hall P, Wiklund K, et al. Cancer risk after
iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83: 1072-1077. |
| (65) |
Hall P, Boice JD Jr, Berg G, et al. Leukaemia incidence after iodine-131
exposure. Lancet 1992; 340: 1-4. |
| (66) |
Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper
DS, Ridgway EC. Radioactive iodine therapy and breast cancer: a follow-up
study of hyperthyroid women. Am J Epidemiol 1988; 127: 969-980. |
| (67) |
Stoffer SS, Hamburger JI. Inadvertent 131I therapy for hyperthyroidism
in the first trimester of pregnancy. J Nucl Med 1976; 17: 146-149. |
| (68) |
Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent
fertility and birth histories of children and adolescents treated with 131I
for thyroid cancer. J Nucl Med 1976; 17: 460-464. |
| (69) |
Robertson JS, Gorman CA. Gonadal radiation dose and its genetic significance
in radioiodine therapy of hyperthyroidism. J Nucl Med 1976; 17: 826-835. |
| (70) |
Toft AD, Irvine WJ, Sinclair I, McIntosh D, Seth J,
Cameron EHD. Thyroid function after surgical treatment of thyrotoxicosis:
a report of 100 cases treated with propranolol before operation. N Engl
J Med 1978; 298: 643-647. |
| (71) |
Feek CM, Sawers JSA, Irvine WJ, Beckett GJ, Ratcliffe WA, Toft AD. Combination
of potassium iodide and propranolol in preparation of patients with Graves'
disease for thyroid surgery. N Engl J Med 1980; 302: 883-885. |
| (72) |
Sawyers JL, Martin CE, Byrd BF Jr, Rosenfeld L. Thyroidectomy
for hyperthyroidism. Ann Surg 1972; 175: 939-947. |
| (73) |
Blichert-Toft M, Jorgensen SJ, Hansen JB, Watt-Boolsen S, Christiansen
C, Ibsen J. Long-term observation of thyroid function after surgical treatment
of thyrotoxicosis. Acta Chir Scand 1977; 143: 221-227. |
| (74) |
Toft AD, Kellett HA, Sawers JSA, et al. What is the
significance of raised plasma TSH levels after thyroid surgery? Scott Med
J 1982; 27: 216-219. |
| (75) |
Evered D, Young ET, Tunbridge WMG, et al. Thyroid function after subtotal
thyroidectomy for hyperthyroidism. BMJ 1975; 1: 25-27. |
| (76) |
Scott GR, Forfar JC, Toft AD. Graves' disease and atrial
fibrillation: the case for even higher doses of therapeutic iodine-131.
BMJ 1984; 289: 399-400. |
| (77) |
Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation.
Stroke 1988; 19: 15-18. |
| (78) |
Hamburger JI. Solitary autonomously functioning thyroid
lesions: diagnosis, clinical features and pathogenetic considerations. Am
J Med 1975; 58: 740-748. |
| (79) |
Molnar GD, Wilbur RD, Lee RE, Woolner LB, Keating FR Jr. On the hyperfunctioning
solitary thyroid nodule. Mayo Clin Proc 1965; 40: 665-684. |
| (80) |
Ng Tang Fui SC, Maisey MN. Standard dose 131I therapy
for hyperthyroidism caused by autonomously functioning thyroid nodules.
Clin Endocrinol (Oxf) 1979; 10: 69-77. |
| (81) |
Ross DS, Ridgway EC, Daniels GH. Successful treatment of solitary toxic
thyroid nodules with relatively low-dose iodine-131, with low prevalence
of hypothyroidism. Ann Intern Med 1984; 101: 488-490. |
| (82) |
Goldstein R, Hart IR. Follow-up of solitary autonomous
thyroid nodules treated with 131I. N Engl J Med 1983; 309: 1473-1476. |
| (83) |
Othman S, Phillips DIW, Parkes AB, et al. A long-term follow-up of postpartum
thyroiditis. Clin Endocrinol (Oxf) 1990; 32: 559-564. |
| (84) |
Kampmann JP, Johansen K, Hansen JM, Helweg J. Propylthiouracil
in human milk: revision of a dogma. Lancet 1980; 1: 736-737. |
| (85) |
Momotani N, Yamashita R, Yoshimoto M, Noh J, Ishikawa N, Ito K. Recovery
from foetal hypothyroidism: evidence for the safety of breast-feeding while
taking propylthiouracil. Clin Endocrinol (Oxf) 1989; 31: 591-595. |
| (86) |
Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K. Antithyroid
drug therapy for Graves' disease during pregnancy: optimal regimen for fetal
thyroid status. N Engl J Med 1986; 315: 24-28. |
| (87) |
Amino N, Kuro R, Tanizawa O, et al. Changes of serum anti-thyroid antibodies
during and after pregnancy in autoimmune thyroid diseases. Clin Exp Immunol
1978; 31: 30-37. |
| (88) |
Roti E, Robuschi G, Gardini E, et al. Comparison of
methimazole, methimazole and sodium ipodate, and methimazole and saturated
solution of potassium iodide in the early treatment of hyperthyroid Graves'
disease. Clin Endocrinol (Oxf) 1988; 28: 305-314. |
| (89) |
Libert F, Lefort A, Gerard C, et al. Cloning, sequencing and expression
of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies.
Biochem Biophys Res Commun 1989; 165: 1250-1255. |